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the Ministry of Health and $19.8 million in societal costs
to the province of Quebec.
CONCLUSION: As Quebec is facing a new epidemic cy-
cle of MCD, the results of this analysis suggest that a
planned MIP to be implemented in September 2001,
would be cost-beneficial as opposed to delaying mass im-
munization until another outbreak occurs.
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OBJECTIVE: This study aims to determine the burden of
illness of severe sepsis (a systemic response to infection in
critically ill patients that often leads to death) in Ger-
many by calculating the direct and indirect patient-
related costs for patients with severe sepsis.
METHODS: Direct ICU costs were determined by a bot-
tom up approach, retrospectively evaluating 385 elec-
tronic records of patients with severe sepsis from three
adult intensive-care units in three university hospitals in
Germany for resource use (medication, laboratory tests,
microbiological analyses, disposables, and clinical proce-
dures), linking the findings with assessed centre-specific
unit costs and adding centre-specific personnel and basic
bed (“hotel”) costs. Indirect costs of illness, those result-
ing from unfitness for work, early retirement, and prema-
ture death, were calculated according to the human capi-
tal approach, using official German statistics.
RESULTS: The mean direct ICU cost of care was € 25,696
per patient. The combination of the incidence range
(45,000–94,000 severe sepsis cases per year in Germany)
with these mean total direct costs yielded a direct cost
range from € 1,130 Mio to € 2,440 Mio for severe sepsis
in Germany. The productivity loss due to temporary
morbidity counts was € 151–326 Mio. Productivity loss
due to permanent morbidity amounts to € 638 to 1,377
Mio and the loss due to premature death is € 3,275 to
7,071 Mio. Direct and indirect costs add up to € 5,194 to
11,214 Mio for the total cost or burden of illness due to
severe sepsis in Germany.
CONCLUSIONS: This study shows that the burden of ill-
ness imposed by severe sepsis in Germany is considerable.
The largest part is as a result of indirect costs due to pro-
ductivity losses, especially early retirement and premature
death. Direct costs represent about 23% of total costs.
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OBJECTIVE: As an attenuated varicella vaccine is avail-
able, the question as to whether varicella could be elimi-
nated in an acceptable time frame under cost-effective
conditions in European countries arises.
METHODS: Epidemiological data and results from mod-
eling studies conducted in France, Italy, Spain, and Ger-
many were analysed and compared. Input data for the
German decision-analytic model were mainly taken from
a seroprevalence study (4,602 sera) and a large epidemio-
logical survey (1334 cases) in 1999. For France, an epide-
miological model was developed and a prospective obser-
vational study of1832 cases was performed. The Spanish
Markov model used data from a seroprevalence study,
from hospitalizations, and from the available literature.
The Italian figures were estimated from a one-year senti-
nel network in 1997. Costs were defined as costs of the
vaccination program. Monetary benefits were defined as
direct and indirect cost savings afforded by vaccination
compared to a strategy not involving vaccination. Effec-
tiveness was measured by the number of infections
avoided.
RESULTS: The age distribution of diagnosed cases in It-
aly and Germany were similar. The complication rates in
Italy (3.5%) and France (2%) were lower than in Ger-
many (5.7%). Indirect costs were the major contributors
to disease cost and accounted for 67% of the cost in
Spain and 80% in Germany. For all countries, vaccina-
tion programs dominated the non-vaccination strategy by
saving costs for society and avoiding infections. Cost-
benefit ratios varied between 1.61 (Spain) and 4.1 (Ger-
many). The German model shows that with a coverage
rate of 85% it would be possible to eliminate varicella
within 15 years.
CONCLUSION: Indirect costs turned out to be the most
important cost factor. From an economic point of view, a
universal vaccination program is justified. The most con-
venient and cost-effective means would be the implemen-
tation of a routine vaccination program using a com-
bined measles, mumps, rubella and varicella vaccine.
PIN14
A STUDY ON THE HEALTH EFFECTS OF FLU 
AND FLU-LIKE ILLNESSES IN THE WORKING 
POPULATION AND THEIR COST IMPACT ON A 
BIG CORPORATION IN HONG KONG
Lee KK, Chan TY, Lau JT, Kwong SK, Lee WS
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: The economic impact of flu and flu-like
illnesses (FFLIs) in Hong Kong has never been investi-
gated. Such data will facilitate the development of a cost-
effective health-care policy against the diseases. The ob-
jectives of the study include: 1) to determine the incidence
and health effects of FFLIs, and 2) to estimate the cost
